Retrospective analysis explores worsening outcomes after initial treatment progression in plasma cell leukemia, suggesting new therapeutic advances.
Key Points
This study aims to analyze clinical outcomes and patterns of progression in patients with primary plasma cell leukemia after first-line therapy.
Retrospective analysis of 104 patients with pPCL treated at a cancer center from 2006 to 2024.
Clinical characteristics, treatments, time to next treatment, and overall survival were assessed using Kaplan-Meier methods.
Analysis included patients who experienced symptomatic and asymptomatic progression.
63% of patients died; median overall survival was 39 months.
Median time to next treatment after first-line therapy was 10 months, which decreased with subsequent lines (3rd line: 6 months; 4th line: 4 months; 5th line: 3 months).
Patients with t(11;14) receiving anti-BCL-2 therapy had a median time to next treatment of 13 months.